Differential Role of Liver X Receptor (LXR) \( \alpha \) and LXR\( \beta \) in the Regulation of UDP-Glucuronosyltransferase 1A1 in Humanized UGT1 \( \alpha \) Mice

Eva Hansmann, Elvira Mennillo, Emiko Yoda, Mélanie Verreault, Olivier Barbier, Shujuan Chen, and Robert H. Tukey

Laboratory of Environmental Toxicology, Department of Pharmacology, University of California, San Diego, La Jolla, California (E.H., E.M., E.Y., S.C., R.H.T.); Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan (E.Y.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté de Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)

Received November 29, 2019; accepted January 14, 2020

ABSTRACT

Liver X receptors (LXRs), LXR\( \alpha \) and LXR\( \beta \), are nuclear receptors that regulate the metabolism of cholesterol and bile acids and are activated by oxysterols. Humanized UGT1 (hUGT1) mice express the 9-human UGT1A genes associated with the UGT1 locus in a Ugt1-null background. The expression of UGT1A1 is developmentally delayed in the liver and intestines, resulting in the accumulation of serum bilirubin during the neonatal period. Induction of UGT1A1 in newborn hUGT1 mice leads to rapid reduction in total serum bilirubin (TSB) levels, a phenotype measurement that allows for an accurate prediction on UGT1A1 expression. When neonatal hUGT1 mice were treated by oral gavage with the LXR agonist T0901317, TSB levels were dramatically reduced. To determine the LXR contribution to the induction of UGT1A1 and the lowering of TSB levels, experiments were conducted in neonatal hUGT1/Lxr\( \alpha \)\( ^{-/-} \), hUGT1/Lxr\( \beta \)\( ^{-/-} \), and hUGT1/Lxr\( \alpha \beta \)\( ^{-/-} \) mice treated with T0901317. Induction of liver UGT1A1 was dependent upon LXR\( \alpha \), with the induction pattern paralleling induction of LXR\( \alpha \)-specific stearoyl CoA desaturase 1. However, the actions of T0901317 were also shown to display a lack of specificity for LXR, with the induction of liver UGT1A1 in hUGT1/Lxr\( \alpha \)\( ^{-/-} \) mice, a result associated with activation of both pregnancy X receptor and constitutive androstane receptor. However, the LXR agonist GW3965 was highly selective toward LXR\( \alpha \), showing no impact on lowering TSB values or inducing UGT1A1 in hUGT1/Lxr\( \alpha \beta \)\( ^{-/-} \) mice. An LXR-specific enhancer site on the UGT1A1 gene was identified, along with convincing evidence that LXR\( \alpha \) is crucial in maintaining constitutive expression of UGT1A1 in adult hUGT1 mice.

SIGNIFICANCE STATEMENT

It has been established that activation of LXR\( \alpha \), and not LXR\( \beta \), is responsible for the induction of liver UGT1A1 and metabolism of serum bilirubin in neonatal hUGT1 mice. Although induction of the human UGT1A1 gene is initiated at a newly characterized LXR enhancer site, allelic deletion of the Lxr\( \alpha \) gene drastically reduces the constitutive expression of liver UGT1A1 in adult hUGT1 mice. Combined, these findings indicate that LXR\( \alpha \) is critical for the developmental expression of UGT1A1.
administration of ligands known to activate either liver or intestinal constitutive androstane receptor (CAR) (Cai et al., 2010; Fujiiwara et al., 2012), the pregnane X receptor (PXR) (Chen et al., 2005, 2012), or the peroxisome proliferator–activated receptor α (PPARα) (Senkeo-Effenberger et al., 2007) result in the induction of UGT1A1 and the simultaneous metabolism and elimination of circulating TSB.

The liver X receptor (LXR) was first identified in the 1990s as an orphan member of the nuclear receptor superfamily and later found to be activated by endogenous oxysterols (Peet et al., 1998a). LXR consists of two isoforms, LXRα and LXRβ. LXRα is expressed in all tissues (Song et al., 1994), in contrast, the expression of LXRβ is restricted to the liver, intestine, kidney, spleen, macrophages, and adipose tissue (Willy et al., 1995). LXR is largely involved in the regulation of cholesterol homeostasis protecting the cells from cholesterol overload by stimulating reverse cholesterol transport (Millatt et al., 2003). Furthermore, LXR has been linked to other major physiologic functions, including lipid metabolism (Ulven et al., 2005; Cha and Repa, 2007), glucose homeostasis (Grefhorst et al., 2005; Oosterveer et al., 2010), steroidogenesis, immunity, and inflammation (Zelcer and Tontonoz, 2006).

LXRα and LXRβ were cloned in 1995 (Mangelsdorf and Evans, 1995; Willy et al., 1995), and later confirmed that the ligand-binding and DNA-binding domains of the receptors were 77% homologous (Alberti et al., 2000). Following confirmation that expression of the LXRs displayed differential tissue specificity (Shinar et al., 1994; Willy et al., 1995) yet both bound to similar LXR enhancer sequences, it had been speculated and later demonstrated that activation of the LXRα/RXR and LXRβ/RXR complexes have different roles in gene expression (Annicotte et al., 2004; Hong and Tontonoz, 2008). This was first demonstrated when Lxrα−/− and Lxrβ−/− mice were placed on a normal or cholesterol high diet (Alberti et al., 2001). The cholesterol-enriched diet had a profound effect on LXRα−/− mice, inducing fatty liver, increased liver mass, and increased cholesterol levels, eventually leading to impaired liver function. The Lxrβ−/− mice were resistant to cholesterol-induced fatty liver formation. There are not highly selective LXRα or LXRβ ligands, making it difficult to isolate the actions of the different LXR receptors on gene expression or function. Yet, activation of LXR by nonselective LXR agonists in Lxrα−/− or Lxrβ−/− mice can isolate the direct actions of these receptors on gene expression. For example, the LXR agonist T0901317-induced hepatic stearoyl CoA desaturase (SCD1) expression only in wild-type or Lxrβ−/− mice and not Lxrα−/− mice, demonstrating that LXRα controls SCD1 expression (Zhang et al., 2014). There is little information on the direct impact of LXR toward the induction and regulation of the UGT1A1 gene. We have now taken a direct approach to evaluate the role of the LXR receptors on the induction of the UGT1A1 gene by deleting LXRα, LXRβ, or LXRα and LXRβ in hUGT1 mice.

Materials and Methods

Materials. UDP-glucuronic acid and bilirubin were obtained from Sigma (St. Louis, MO). SN-38 and T0901317 were obtained from Cayman Chemical (Ann Arbor, MI). SN-38 glucuronide was from Santa Cruz Biotechnology (Santa Cruz, CA). Internal standards deuterated d10-CPT-11 and d3-SN-38 were purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). Rabbit anti-GAPDH monoclonal antibody was purchased from Abcam (Cambridge, UK). Mouse anti-GAPDH monoclonal antibody was obtained from Santa Cruz Biotechnology (Dallas, TX). Anti-mouse IgG horseradish peroxidase (HRP) conjugated antibody and anti-rabbit IgG HRP conjugated antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA). Human hepatoma (HepG2) and human embryonic kidney (HK293) cells were obtained from the American Type Culture Collection (Rockville, MD). The cells were cultured and passaged per standard protocol.

Animal Studies. Humanized UGT1 mouse were previously generated by introducing a bacterial artificial chromosome (BAC) clone encoding the entire UGT1 locus into mice [transgenic(Tg)UGT1/UGT1] mice (Chen et al., 2005) and crossing TgUGT1 mice with Ugt1−/− mice (Nguyen et al., 2008) until TgUGT1/UGT1−/− mice (hUGT1 mice) were created (Fujiiwara et al., 2010). A breeding strategy between hUGT1, Loxα−/−, Loxα−/−, and Loxαβ−/− mice was developed that resulted in the generation of hUGT1/Loxα−/−, hUGT1/Loxαβ−/−, and hUGT1/Loxαβ−/− mice. The Lxr-null mice were originally developed by the David Mangelsdorf laboratory (Repa et al., 2000) and were generously obtained from Christopher Glass at the University of California, San Diego (UCSD). hUGT1/CAR−/− mice were developed previously (Fujiiwara et al., 2012). All mouse strains were housed in a pathogen-free UCSD Animal Care Facility and received food and water ad libitum. All animal protocols were reviewed and approved by the UCSD Animal Care and Use Committee. Neonatal male and female 10-day-old mice were treated orally with either propylene glycol/tween 4:1 (vehicle) or 50 mg/kg T0901317 dissolved in vehicle or GW3965 (75 mg/kg), and tissues were collected 48 hours after treatment.

Bilirubin Measurements. Blood was obtained from the submandibular vein and centrifuged at 16,000g for 2 minutes. Serum samples were immediately measured for TSB levels using a Unistat Bilirubinometer (Reichert, Depew, NY).

Liver Tissue Sections. Entire livers were dissected from mice, snap-frozen in liquid nitrogen, and stored at −80°C. Frozen tissues were pulverized and the powder aliquoted for further RNA and protein extraction.

Total RNA Preparation and Real-Time Reverse Transcription Polymerase Chain Reaction. Total RNA was isolated from liver tissue of treated and control mice according to the TRIzol reagent protocol as supplied by the supplier (Thermo Fisher Scientific, Waltham, MA). The samples were prepared for reverse transcription by using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Quantitative polymerase chain reaction (qPCR) using newly synthesized cDNA was carried out using a CFX96 QPCR system (Bio-Rad) by employing SsoAdvanced SYBR Green reagent (Bio-Rad). Primers used in these studies are shown in Table 1.

Western Blot Analysis. Tissues were homogenized in RIPA lysis buffer (EMD Millipore Corporation, Temecula, CA) supplemented with protease and phosphatase inhibitor cocktail (1:100 each). Protein solutions were pooled to have a total of four samples for each genotype and condition. Western blots were prepared for 2 hr in 5% milk in 1× TBST. Membranes were probed for 1 hr at room temperature with rabbit or mouse primary antibodies, followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies. Immunoreactive bands were visualized using the Clarity Western ECL Substrate (Bio-Rad Laboratories, Hercules, CA). Molecular weights were determined using prestained molecular weight markers.

TABLE 1

Sequence of primers used in qPCR analysis

<table>
<thead>
<tr>
<th>Genes</th>
<th>Oligonucleotide Sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human UGT1A1</td>
<td>Forward: CACCATGTCGCAATATTGTT</td>
</tr>
<tr>
<td>Human UGT1A3</td>
<td>Reverse: CCAACAATTCAGATCTTCA</td>
</tr>
<tr>
<td>Human UGT1A4</td>
<td>Forward: CCAACCCGAGCCACACTTC</td>
</tr>
<tr>
<td>Human UGT1A6</td>
<td>Reverse: CTGGAGACTTGATCATC</td>
</tr>
<tr>
<td>Human UGT1A9</td>
<td>Forward: TACCAATGAGTCGTAGGG</td>
</tr>
<tr>
<td>Scl-1</td>
<td>Reverse: CCACCATGAAGTGTGTTG</td>
</tr>
<tr>
<td>Scl-2</td>
<td>Forward: CCAGCAGCGTGGTCAATG</td>
</tr>
<tr>
<td>LXRα, LXRβ</td>
<td>Reverse: TGTCGATGGTGATGG</td>
</tr>
<tr>
<td>Cyp2h10</td>
<td>Forward: CCACCATGAAGTGTGTTG</td>
</tr>
<tr>
<td>Cyp3a11</td>
<td>Reverse: ATGGTGTTGATGG</td>
</tr>
<tr>
<td>Cyp4a10</td>
<td>Forward: CACCATGTCGCAATATTGTT</td>
</tr>
<tr>
<td>Cph</td>
<td>Reverse: CCAACAATTCAGATCTTCA</td>
</tr>
</tbody>
</table>
Activation of LXRe Induces Human UGT1A1 in hUGT1 Mice

TABLE 2

Sequence of oligonucleotides used in LXRe binding element analysis
Bold nucleotides represent potential LXRe/RXR binding sequences and underlined nucleotides correspond to mutated bases.

<table>
<thead>
<tr>
<th>Oligonucleotides</th>
<th>Sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR4 —9903 wt</td>
<td>ATAGAGAGGGTGCACAGGAGACCTAAGG ACT</td>
</tr>
<tr>
<td>DR4 —9855 wt</td>
<td>TAAAGAGGCTGTCATGGTGATAGGAA GAG</td>
</tr>
<tr>
<td>DR4 —7632 wt</td>
<td>GAGGAGGAGGATGCATCAAGGACCAATTATT ATT</td>
</tr>
<tr>
<td>DR4 —4076 wt</td>
<td>TCTGGAGGTATGTTATGGAGAACACCTTC TAC</td>
</tr>
<tr>
<td>DR4 —8855 wt</td>
<td>TAAACCCGTGACTGTTATTAGGGA CGC</td>
</tr>
<tr>
<td>DR4 —9855 nt</td>
<td>CCCAGGTTGATTTATTTATTTATTTATTTA TTGA</td>
</tr>
<tr>
<td>LRXE consensus</td>
<td>5′-TCAGCTGTCTGCGCCATACAAACG TTG</td>
</tr>
<tr>
<td>ChIP</td>
<td>5′-CAGCGATCTAGACTCTTGGA AAAAA</td>
</tr>
<tr>
<td>UGT1A3 LRXE</td>
<td>5′-CTGGAATCAAGCTACTGTTG GTT</td>
</tr>
<tr>
<td>UGT1A1 —9903 bp</td>
<td>5′-GACAATAGCTGGTCACTGC CAT</td>
</tr>
<tr>
<td>UGT1A1 —9855 bp</td>
<td>5′-GAGACTGGTCACTGCACTG CAT</td>
</tr>
<tr>
<td>UGT1A1 —7632 bp</td>
<td>5′-ATTACGAAAAATATTTTGG CAT</td>
</tr>
<tr>
<td>UGT1A1 —4076 bp</td>
<td>5′-GATACATAAGAGATCTAGCAG CTG</td>
</tr>
<tr>
<td>UGT1A1 —888 bp</td>
<td>5′-GAGCGCTTGGCGTGGTTGTTG GTT</td>
</tr>
<tr>
<td>LRXE consensus (x3)</td>
<td>5′-GAAGCGGATGCTGGTGGTGGTGGATG CTG</td>
</tr>
<tr>
<td>DR4 multicy</td>
<td>5′-TATGGAATCATATTTAAACCTGGGTGATG TG</td>
</tr>
<tr>
<td>DR4 —9903 (x3)</td>
<td>5′-ATAAGGGTGACAGCAGGAGAGA ACCTCAA GACT</td>
</tr>
<tr>
<td>DR4 —9855 (x3)</td>
<td>5′-TAAAGGGGTGACCTAAGCTGGA ACC</td>
</tr>
<tr>
<td>DR4 —4076 (x3)</td>
<td>5′-TCTGGAAGGATATTATTTACAGA ACC</td>
</tr>
<tr>
<td>DR4 —888 (x3)</td>
<td>5′-ACCCTGTAACGCCTGACAACAG ACC</td>
</tr>
</tbody>
</table>

To investigate the potential of LXRe to induce the UGT1A1 gene, 10-day-old neonatal hUGT1 mice were treated once with vehicle (propylene glycol/tween 80, 40:1) or with the LXRe agonist T090137 (50 mg/kg) by oral gavage. After 48 hours, serum was collected for TS assay and the livers collected for RNA extraction. Neonatal hUGT1 mice develop severe levels of serum bilirubin. T090137 treatment of 48 hours reduced TS levels to normal adult levels (Fig. 1A). This drop in TS levels resulted from a significant induction of liver UGT1A1 gene expression (300-fold) as quantitated by qPCR (Fig. 1B). Also, analysis of RNA expression demonstrated there was substantial induction of liver UGT1A3 (200-fold) and UGT1A4 (400-fold), with UGT1A6 and UGT1A9 genes being unaffected (Fig. 1C). We have shown previously that T090137 treatment to transgenic UGT1 mice induced the UGT1A3 gene in liver and intestinal tissue, along with induction of UGT1A3 directed glucuronidation activity toward chemodioxoylic acid (CDCA) and lithocholic acid (LCA) (Verreault et al., 2006).

The LXRe Receptors Display Gene Specificity. To examine the specificity of the LXRe receptors toward induction of liver UGT1A1, hUGT1, hUGT1/LrxaΔ−/−, hUGT1/LrxbΔ−/−, and hUGT1/LrxaΔ−/−(UGT1/LrxbΔ−/−) mice were developed. To confirm the knockout conditions in these mice, qPCR analysis was performed to verify the elimination of LXRe mRNA expression in hUGT1/LrxaΔ−/− and hUGT1/LrxbΔ−/− mice and the elimination of LrxbΔ−/− mRNA
expression in hUGT1/Lxrβ−/− and hUGT1/Lxrαβ−/− mice (Fig. 2, A and B). Interestingly, there was a consistent reduction in Lxrα gene expression in Lxrβ−/− mice treated with T090137, yet the values were not statistically significant. Knockout of the Lxr genes leads to a loss of function, as demonstrated in gene expression patterns of the LXRα target genes stearoyl CoA desaturase-1 (Scd1) and Scd2 (Chu et al., 2006; Caputo et al., 2014; Zhang et al., 2014). These proteins catalyze the conversion of saturated fatty acids into monounsaturated fatty acids and have previously been described to be activated by LXR agonists in either an sterol regulatory element-binding-1c (SREBP-1c) dependent or independent manner. The oral treatment of neonatal hUGT1 and hUGT1/Lxrb−/− mice with T090137 resulted in transcriptional activation of Scd1 and Scd2 genes (Fig. 2, C and D). Mice lacking the Lrxa gene did not show increases in SC1D1 or SC2D1 RNA (Fig. 2, C and D).

**Induction of UGT1A1 by LXR.** Using these same tissues, the induction profile of the UGT1A1 gene was like that of Scd1, with greater induction in hUGT1 and hUGT1/LXrβ−/− mice and significantly reduced induction in hUGT1/Lxrα−/− and hUGT1/Lxrb−/− mice (Fig. 3B). However, the induction of the UGT1A1 gene in hUGT1/Lxrα and hUGT1/Lxrb−/− was still considerable with approximately 30% of those values detected in the liver from hUGT1 mice. Surprisingly, the TSB values in the hUGT1 mice and the other LXR variants were all greatly reduced when compared with vehicle-treated mice (Fig. 3A). The phenotype changes in serum TSB values in hUGT1, hUGT1/Lxrα−/−, hUGT1/Lxrb−/−, and hUGT1/Lxrb−/− mice suggests that UGT1A1 was induced in each of these strains following T090137 treatment. This was confirmed by Western blot analysis showing that induction of liver UGT1A1 occurs in all strains treated, with liver abundance reflecting that of gene expression (Fig. 3C). Also, glucuronidation analysis using liver extracts has confirmed that bilirubin (Fig. 3D) and SN-38 (Fig. 3E), substrates that are conjugated by UGT1A1, show a functional induction pattern like UGT1A1 gene expression. Because the induction levels of UGT1A1 in hUGT1/Lxrb−/− mice, which do not express functional LXR, are like those observed in hUGT1/Lxrb−/− mice, this finding indicates that LXRβ plays a negligible role in the induction of UGT1A1 in neonatal mice.

**T090137 and LXR Elicit Cross-Talk with Other Nuclear Receptors.** The dramatic induction of UGT1A1 by T090137 in all LXR mouse lines led us to examine in greater detail this unusual property of T090137. In the liver, the Cyp2b10, Cyp3a11, and Cyp4a10 genes are significantly induced in hUGT1 mice (Fig. 4, A–C) by T090137. It is interesting to note that in the absence of LXRα, T090137 elicits a highly synergistic Cyp3a11 induction response. This observation indicates that activation of PXR by T090137, which can induce Cyp3a11, may be repressed by activated LXRα. In contrast, induction of Cyp4a10, which can be induced by PPARα, is not induced above control values in LXRα deficient mice, indicating that induction of Cyp4a10 by PPARα requires functional LXRα. In both of these examples, activation of either PXR or PPARα by T090137 is interconnected with LXRα and not LXRβ. Different from these examples, however, is the induction pattern by CAR activation of the Cyp2b10 gene in hUGT1, hUGT1/Lxrα−/−, hUGT1/Lxrb−/−, hUGT1/Lxrb−/−, and hUGT1/CAR−/− mice (Fig. 4C). Western blot analysis of liver extracts from these treated mice demonstrates that the induction of Cyp2b10 by T090137 is CAR dependent because induction is significantly reduced in hUGT1/CAR−/− mice (Fig. 4D). Thus, the human UGT1A1 gene can be induced by T090137 through activation of PXR, PPARα, and CAR, in addition to the more dominant action of LXRα.

**Induction of Liver UGT1A1 by GW3965.** In addition to T090137, the synthetic LXR agonist GW3965 has been used as an alternative agent to examine LXR-activated target genes. We treated 10-day-old neonatal hUGT1, hUGT1/Lxrb−/−, and hUGT1/Lxrα−/− mice with GW3965 (75 mg/kg) and examined TSB values and UGT1A1 gene expression patterns after 2 days of exposure (Fig. 5A). TSB values were dramatically reduced in hUGT1 and hUGT1/Lxrb−/− mice, but the values did not change in hUGT1/Lxrα−/− mice, confirming that induction of UGT1A1 follows activation of LXrα and not LXrβ. This was confirmed by two additional sets of data. First, the induction of liver UGT1A1 gene expression did not occur in hUGT1/Lxrα−/− mice (Fig. 5B), and second, Western blot analysis shows induction of UGT1A1 in hUGT1 and hUGT1/Lxrb−/− mice only (Fig. 5C). Based upon current knowledge of the specificity of T090137 and GW3695.
to activate both LXRα and LXRβ, the induction of liver UGT1A1 is driven selectively by activated LXRα. It can be noted that the TSB levels following oral GW3965 treatment are not as low as noted for T0901317 treatment (Fig. 1). It is possible that T0901317, which is able to activate not only LXR but also PXR and CAR, is also inducing UGT1A1 in intestinal tissue, a site that contributes toward bilirubin clearance (Chen et al., 2017).

Identification of a Functional LXR Response Elements within the UGT1A1 Gene Promoter. A computer-assisted analysis (Quandt et al., 1995) of the UGT1A1 promoter gene sequence revealed the
presence of five degenerated LXR response element (LXRE) sequences (Willy et al., 1995) localized at positions −9903, −9855, −7632, −4076, and −888 bp of the promoter (Supplemental Fig. 1). Occupancy of these response elements by LXRα in living cells was analyzed through a ChIP assay performed on DNA from vehicle- or T0901317-treated HepG2 cells (Fig. 6). Only the DNA sequences encompassing the −9855 bp LXRE of the human UGT1A3 promoter (positive control) (Verreault et al., 2006) were precipitated by the anti-LXRα antibody in T0901317-treated cells (Fig. 6, A and C, Lane 8) but not in untreated cells (Lane 3). None of the other LXRE-like sequences found in the UGT1A1 gene promoter were PCR amplified in any of the precipitated DNA preparations, suggesting that they are not occupied by LXRα/β. Because T0901317 was also reported as an activator of PXR (Mitro et al., 2007), DNA was also immunoprecipitated with an anti-PXR antibody (Lanes 4 and 9). No amplifications were observed.

Transient transfection with a −9855 bp LXRE-TK-pGL3 construct revealed that coexpression of LXRα and RXRα increased activity of the LXRE in human hepatoma HepG2 cells, an effect that was dose-dependently enhanced in the presence of T0901317 and GW3965 (0.1–10 μM) (Fig. 6B). In EMSA, a clear binding was observed when a radiolabeled probe encompassing the −9855 bp LXRE sequence was incubated in the presence of both LXRα and RXRα (Fig. 6C, Lane 4). Introducing mutated bases within the 3' -half-site of the LXRE (Table 1) completely abolished the formation of this binding (Fig. 6, lane 5). In competition experiments, LXRα/RXRα binding to the WT probe was efficiently competed by itself and the consensus LXRE (Fig. 6, Lanes 6–8 and 12–14, respectively). In contrast, the mutated response elements failed to significantly compete for LXRα binding (lanes 9–11). Overall, these data identify the LXRE motif at position −9855 bp in the human UGT1A1 gene promoter as a functionally active LXR response element.

The Role of LXRα and Expression of UGT1A1 in Adult hUGT1 Liver. There is a limited expression of human UGT1A1 in the liver tissue of neonatal hUGT1 mice, but in adult hUGT1 mice there is adequate expression. When we examined the constitutive expression pattern of UGT1A1 by qPCR and Western blot analysis, there was an excellent agreement with gene expression and protein detection (Fig. 7). However, it is clear from this analysis that LXRα plays a key role in basal or constitutive expression of liver UGT1A1, with greatly reduced expression in hUGT1/Lxrα−/− and hUGT1/Lxrαβ−/− mice.
When the Lxrα allele is either null or exists in the heterozygous state (hUGT1/Lxrα+/−), the expression of liver UGT1A1 is greatly reduced. This indicates that both Lxrα alleles are necessary to maintain the full expression of UGT1A1.

Discussion

Liver X receptors α and β have been shown to play pivotal roles in the transcriptional control of lipid metabolism (Edwards et al., 2002; Wagner et al., 2003; Wang and Tontonoz, 2018). Activated LXRαs regulate the expression of genes that are linked to functional control of cholesterol absorption, transport, efflux, excretion, and conversion to bile acids (Peet et al., 1998a; Zhang et al., 2012). Under these conditions, the LXRαs bind directly to these genes at LXR enhancer sequences to induce transcription (Sabol et al., 2005). Also, LXRαs regulate fatty acid metabolism by controlling the lipogenic transcriptional factor sterol regulatory element-binding protein 1c (Repa et al., 2000; Wagner et al., 2003) that in turn regulates genes that encode proteins involved in fatty acid elongation and desaturation (Schultz et al., 2000). Along with these important regulatory events, LXRαs also drive the incorporation of polyunsaturated fatty acids into phospholipids. Each of these regulatory events leads to the proper homeostasis of the membrane environment and lipid composition, which if disrupted can impact diseases such as atherosclerosis, diabetes, fatty liver disease, and cancer.

Although there is approximately 78% amino acid similarity between LXRα and LXRβ, the genes encoding these proteins in mice exist on different chromosomes, with Lxrα residing on chromosome 2 and Lxrβ on chromosome 7. The evolutionary split of these genes indicates that their expression may differ in selective tissues coupled with changes in receptor function. The LXRαs are activated by naturally occurring oxysterols and by synthetic nonsteroidal compounds such as T0901317 and GW3965. However, LXRα and LXRβ are expressed differently with regards to abundance and tissue specificity. Annicotte et al. (2004) employed selectively in situ hybridization in embryonic and adult tissue to demonstrate that LXRα is highly expressed in metabolically active tissues such as the liver, intestine, and adipose tissue while LXRβ is ubiquitously expressed. Although there is a commonality in the ability of ligands to activate the LXRαs, there are several key examples that the LXRαs elicit unique functional roles. For example, mice lacking LXRα accumulate massive amounts of cholesterol in the liver when fed a high-cholesterol diet (Peet et al., 1998b). This results from the inability of cytochrome P450 7A1, a key LXRα target gene, to metabolize cholesterol to bile acids. This does not occur when cholesterol is fed to LXRβ-deficient mice. Numerous other examples have been reported favoring a selective advantage in controlling physiologic functions or gene regulation for one of the receptors over the other (Alberti et al., 2001; Jakobsson et al., 2014; Zhang et al., 2014; Whitfield et al., 2016; Endo-Umeda et al., 2018).

In the absence of ligand, the LXR/RXR complexes bind to transcriptional corepressors, such as the nuclear corepressor 1 (NCOR1), and repress target gene expression (Chen and Evans, 1995; Horlein et al., 1995; Li et al., 2013). Upon ligand binding, LXRαs dissociate from NCOR1 and assemble with coactivators, leading to modulation of histone acetylation or chromatin remodeling, facilitating transcriptional...
activation. When NCoR1 is selectively deleted in target tissues, LXR becomes activated in the absence of ligand and stimulates transcription of target genes (Li et al., 2013). In neonatal hUGT1 mice that are deficient in intestinal NCoR1, the UGT1A1 gene was derepressed leading to the metabolism of serum bilirubin (Chen et al., 2017). Gene expression data indicated that LXR target genes were in part activated in hUGT1/Ncor1−/− mice, leading us to examine in greater detail the role of LXRα and LXRβ in the potential induction of the UGT1A1 gene. Using neonatal hUGT1 mice deficient in LXRα, LXRβ, or both LXRα and LXRβ that were orally treated with synthetic LXR agonists T0901317 or GW3695, induction of hepatic UGT1A1 was dominated by LXRα. However, the induction patterns of UGT1A1 and TSB values in these mice were quite different when we compared the impact of the two agents. The oral administration of GW3695 led to hepatic induction of UGT1A1 in hUGT1/Lxrα−/− and hUGT1/Lxraβ−/− mice only, which matched the reduction in TSB values. The absence of UGT1A1 induction in hUGT1/Lxra−/− and hUGT1/Lxraβ−/− mice establishes that activated LXRα underlies the induction process.

The most well-characterized synthetic LXR ligand to date is T0901317, but this agent elicited a different pattern of induction. Although the general pattern of UGT1A1 induction in these mice by T0901317 was like that of GW3695, a reduction in TSB was observed in all treatment groups. Also, there was considerable UGT1A1 gene and protein expression detected in hUGT1/Lxra−/− and hUGT1/Lxraβ−/− mice, which showed little induction when these mice were treated with GW3695. We now believe that the induction of hepatic UGT1A1 in hUGT1/Lxra−/− and hUGT1/Lxraβ−/− mice by T0901317 results from activation of additional nuclear receptors, such as PXR and CAR, and not LXR. It has been reported previously that T0901317 can activate PXR and effectively induce PXR target genes such as Cyp3a11 in mice (Shenoy et al., 2004). PXR activation in neonatal hUGT1 mice leads to the induction of UGT1A1 and a reduction in TSB levels (Chen et al., 2012; Fujiiwara et al., 2012) and, in this study, dramatically induces liver CYP3A11 RNA in all four mouse lines. It is interesting to note that T0901317 induced Cyp3a11 gene induction in hUGT1/Lxra−/− and hUGT1/Lxraβ−/− mice two- to threefold greater than in hUGT1 and hUGT1/Lxra−/− mice. This superinduction of the Cyp3a11 gene by T0901317 in hUGT1/Lxra−/− and hUGT1/Lxraβ−/− mice indicates that LXRα expression serves to inhibit full activation of the PXR receptor or has inhibitory action associated with the Cyp3a11 gene. Also, T0901317 induced hepatic CYP2B10 in a fashion that was independent of the expression of LXRα and LXRβ. The induction of CYP2B10 was driven by activated CAR because no induction of UGT1A1 occurred in hUGT1/Car−/− mice. It has been suggested that there is functional cross-talk between LXRα and CAR with activation of CAR leading to the inhibition of LXR target genes (Zhai et al., 2010). If this mechanism is in play following T0901317 exposure, which activates both LXRα and CAR, induction of LXRα target genes may be attenuated as a result of the inhibitory actions of CAR. The use of T0901317 as an LXR agonist to examine the physiologic impacts and gene expression patterns following LXR activation can be complicated knowing that it serves as an agonist for PXR, farnesoid X receptor (Houck et al., 2004), and CAR while inducing cross-talk between LXRα, CAR, and PXR.

With the treatment of hUGT1 neonatal mice with T0901317 or GW3695 we present convincing evidence the LXRα is directly activating the UGT1A1 gene in the liver, an event that leads to the metabolism and clearance of serum bilirubin. This analysis is based upon the induction patterns of UGT1A1 in hUGT1 mice that are deficient either LXRα or LXRβ in hepatic tissue. However, it does not account for the relative abundance of LXRα and LXRβ in this tissue or the relative binding affinities of the ligands to the receptors. Few examples document the abundance of these receptors in different tissues. Using LXRα- and LXRβ-dCas9s to generate antisense RNA for in situ hybridization experiments, Annicotte et al. (2004) examined the developmental expression of the receptors in postcoitum at different days as well as in adult tissue. The conclusions from this experiment indicated that LXRα and LXRβ were both expressed in liver tissue but the abundance of LXRβ RNA dropped as the pregnancy came closer to term, with LXRβ RNA being reduced in adult liver. However, LXRβ is expressed in liver tissue. Because GW3695 has a greater binding affinity toward LXRβ, we can be confident that both LXRα and LXRβ are being activated in liver tissue following oral administration. With the identification of the LXRβ binding sequence flanking the human UGT1A1 gene and the complete absence of UGT1A1 induction by GW3695 in hUGT1/Lxrα−/− mice, our findings strongly implicate LXRα as a regulator of liver UGT1A1 gene expression.

The initial discovery that LXRα could be activated by oxysterols was the first of many clues suggesting that LXRα controlled cholesterol homeostasis, eventually implicating the production of bile acids and controlling lipogenesis (Wang and Tontonoz, 2018). Our findings have confirmed that LXRα is a potent regulator of the UGT1A1 gene during development and could serve as a therapeutic target in events that require the regulation of accumulating serum bilirubin. It remains unclear the physiologic advantage of regulating the UGT1A1 gene along with other genes of the UGT1 locus by LXRα because there is no perceived link between oxysterols and the function of UGT1A1. One might consider, however, that oxysterols play an important role in maintaining adequate LXR-driven constitutive expression of the UGT1A1 gene, which is essential in facilitating metabolism and elimination of the major heme metabolic product, bilirubin. Regardless, these findings suggest that events linking abnormal cholesterol and lipid homeostasis to the onset of lipogenic diseases will have an impact on the control and regulation of UGT1A1 and the functional properties of this important protein in endogenous and exogenous drug metabolism.

**Authorship Contributions**

Participated in research design: Hansmann, Mennillo, Yoda, Verreault, Barbier, Chen, Tukey.

Conducted experiments: Hansmann, Mennillo, Yoda, Verreault, Chen. 

Performed data analysis: Hansmann, Mennillo, Yoda, Tukey.

Wrote or contributed to the writing of the manuscript: Hansmann, Barbier, Tukey.

**References**


Activation of LXRXα Induces Human UGT1A1 in hUGT1 Mice

263


Address correspondence to: Robert H. Tukey, Department of Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0722.

E-mail: rtukey@ucsd.edu

Downloaded from dx.doi.org/10.1093/aspetjournals/dct380 at December 29, 2022

Downloaded from dx.doi.org/10.1093/aspetjournals/dct380 at December 29, 2022